GlassScriptPhysician profile
Daniel Keith Dsouza
NPI 1376542654
$2,722.48
in general payments reported to CMS, 2019-2025
25 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $518 · 2021: $513 · 2022: $420 · 2023: $385 · 2024: $363 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.51 | 2020-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $508.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.48 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $182.49 | 2020-2023 | Emgality, Jardiance |
| Glaxosmithkline, LLC. | $179.09 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $177.57 | 2021-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $126.33 | 2019-2021 | |
| Amarin Pharma, INC. | $71.11 | 2020-2021 | |
| Optinose US, INC. | $64.85 | 2020-2025 | |
| Abbott Laboratories | $62.52 | 2022-2023 | Freestyle Libre 3 |
| Pfizer INC. | $46.27 | 2020-2025 | |
| Medtronic, INC. | $41.24 | 2021 | |
| Abbvie INC. | $37.11 | 2019-2021 | |
| Astellas Pharma US INC | $36.70 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $34.93 | 2020-2023 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.16 | 2024-2025 | Cologuard Collection Kit |
| Genentech USA, INC. | $33.83 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.41 | 2023 | Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $30.07 | 2023 | |
| Althera Pharmaceuticals LLC | $22.24 | 2021 | |
| Myocardial Solutions, INC. | $18.67 | 2021 | |
| Ibsa Pharma INC. | $17.03 | 2022 | |
| Endogastric Solutions, INC | $16.14 | 2024 | Esophyx |
| Allergan, INC. | $15.89 | 2020 | |
| Medicure Pharma INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dsouza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.